NCT06176963View on ClinicalTrials.gov

A Study to Evaluate the Usability of the SB11 PFS in Subjects With Wet AMD or Macular Oedema Secondary to RVO

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

November 21, 2023

Primary Completion Date

November 30, 2023

Study Completion Date

December 12, 2023

Conditions
Neovascular Age-related Macular DegenerationMacular EdemaRetinal Vein Occlusion
Interventions
COMBINATION_PRODUCT

SB11 PFS

SB11 provided in a pre-filled syringe (PFS) containing 0.5 mg ranibizumab in 0.05 mL for ITV injection

Trial Locations (3)

Unknown

SB Investigational Site, Katowice

SB Investigational Site, Krakow

SB Investigational Site, Olsztyn

All Listed Sponsors
lead

Samsung Bioepis Co., Ltd.

INDUSTRY

NCT06176963 - A Study to Evaluate the Usability of the SB11 PFS in Subjects With Wet AMD or Macular Oedema Secondary to RVO | Biotech Hunter | Biotech Hunter